Nemolizumab Update: Galderma’s IL-31 Blocker Receives Filing Acceptances for PN and AD in Four More Countries May 7, 2024
AD Pipeline Watch: Inmagene’s Anti-OX40 Monoclonal Antibody Performs Well in Phase 2a AD Trial May 6, 2024
EltaMD Rolls Out Deep Tinted Version of UV Clear and UV Daily Collections, Partners With Key Organizations for Skin Cancer Awareness Month May 6, 2024
Melanoma Monday 2024: Advances in the Early Detection and Treatment of Melanoma Are Changing the Game May 6, 2024